Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/TNRC6B_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/TNRC6B_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/TNRC6B_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/TNRC6B_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/TNRC6B_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/TNRC6B_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/TNRC6B_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/TNRC6B_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/TNRC6B_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/TNRC6B_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:006101311 | Liver | Cirrhotic | regulation of mRNA catabolic process | 70/4634 | 166/18723 | 5.91e-07 | 1.30e-05 | 70 |
GO:003424911 | Liver | Cirrhotic | negative regulation of cellular amide metabolic process | 100/4634 | 273/18723 | 7.34e-06 | 1.13e-04 | 100 |
GO:006115711 | Liver | Cirrhotic | mRNA destabilization | 38/4634 | 84/18723 | 3.34e-05 | 4.13e-04 | 38 |
GO:200063711 | Liver | Cirrhotic | positive regulation of gene silencing by miRNA | 18/4634 | 30/18723 | 4.27e-05 | 5.03e-04 | 18 |
GO:005077911 | Liver | Cirrhotic | RNA destabilization | 39/4634 | 88/18723 | 4.69e-05 | 5.47e-04 | 39 |
GO:00609645 | Liver | Cirrhotic | regulation of gene silencing by miRNA | 25/4634 | 49/18723 | 6.57e-05 | 7.47e-04 | 25 |
GO:006014711 | Liver | Cirrhotic | regulation of posttranscriptional gene silencing | 26/4634 | 52/18723 | 7.35e-05 | 8.23e-04 | 26 |
GO:006014811 | Liver | Cirrhotic | positive regulation of posttranscriptional gene silencing | 18/4634 | 31/18723 | 7.83e-05 | 8.61e-04 | 18 |
GO:006101411 | Liver | Cirrhotic | positive regulation of mRNA catabolic process | 38/4634 | 87/18723 | 8.55e-05 | 9.25e-04 | 38 |
GO:001714811 | Liver | Cirrhotic | negative regulation of translation | 87/4634 | 245/18723 | 1.01e-04 | 1.05e-03 | 87 |
GO:006096611 | Liver | Cirrhotic | regulation of gene silencing by RNA | 26/4634 | 53/18723 | 1.11e-04 | 1.12e-03 | 26 |
GO:006021312 | Liver | Cirrhotic | positive regulation of nuclear-transcribed mRNA poly(A) tail shortening | 10/4634 | 13/18723 | 1.14e-04 | 1.14e-03 | 10 |
GO:000028811 | Liver | Cirrhotic | nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 26/4634 | 56/18723 | 3.40e-04 | 2.91e-03 | 26 |
GO:00602116 | Liver | Cirrhotic | regulation of nuclear-transcribed mRNA poly(A) tail shortening | 10/4634 | 15/18723 | 7.26e-04 | 5.36e-03 | 10 |
GO:19001534 | Liver | Cirrhotic | positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 10/4634 | 15/18723 | 7.26e-04 | 5.36e-03 | 10 |
GO:190015111 | Liver | Cirrhotic | regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay | 11/4634 | 18/18723 | 1.13e-03 | 7.73e-03 | 11 |
GO:00609681 | Liver | Cirrhotic | regulation of gene silencing | 31/4634 | 81/18723 | 4.76e-03 | 2.50e-02 | 31 |
GO:000028911 | Liver | Cirrhotic | nuclear-transcribed mRNA poly(A) tail shortening | 14/4634 | 29/18723 | 5.09e-03 | 2.62e-02 | 14 |
GO:000989622 | Liver | HCC | positive regulation of catabolic process | 335/7958 | 492/18723 | 3.83e-31 | 1.87e-28 | 335 |
GO:003133122 | Liver | HCC | positive regulation of cellular catabolic process | 295/7958 | 427/18723 | 3.20e-29 | 1.45e-26 | 295 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TNRC6B | SNV | Missense_Mutation | | c.4778G>T | p.Arg1593Met | p.R1593M | Q9UPQ9 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-A2-A04P-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD |
TNRC6B | SNV | Missense_Mutation | | c.872N>T | p.Asp291Val | p.D291V | Q9UPQ9 | protein_coding | deleterious(0.01) | possibly_damaging(0.522) | TCGA-A2-A04U-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
TNRC6B | SNV | Missense_Mutation | | c.1277N>T | p.Gly426Val | p.G426V | Q9UPQ9 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A2-A0YC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | PD |
TNRC6B | SNV | Missense_Mutation | | c.4130N>T | p.Ser1377Phe | p.S1377F | Q9UPQ9 | protein_coding | tolerated(0.48) | probably_damaging(0.988) | TCGA-A7-A26H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | PD |
TNRC6B | SNV | Missense_Mutation | novel | c.4237N>A | p.Glu1413Lys | p.E1413K | Q9UPQ9 | protein_coding | deleterious(0) | benign(0.036) | TCGA-A8-A096-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TNRC6B | SNV | Missense_Mutation | rs772135186 | c.1769N>A | p.Arg590His | p.R590H | Q9UPQ9 | protein_coding | deleterious(0.05) | probably_damaging(0.984) | TCGA-AN-A0XU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TNRC6B | SNV | Missense_Mutation | rs267606255 | c.79N>A | p.Glu27Lys | p.E27K | Q9UPQ9 | protein_coding | tolerated(0.14) | benign(0.015) | TCGA-B6-A0I5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TNRC6B | SNV | Missense_Mutation | rs267606255 | c.79N>A | p.Glu27Lys | p.E27K | Q9UPQ9 | protein_coding | tolerated(0.14) | benign(0.015) | TCGA-B6-A1KI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TNRC6B | SNV | Missense_Mutation | | c.769N>A | p.Gly257Arg | p.G257R | Q9UPQ9 | protein_coding | deleterious(0.03) | probably_damaging(0.998) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
TNRC6B | SNV | Missense_Mutation | rs778520882 | c.5N>A | p.Arg2Lys | p.R2K | Q9UPQ9 | protein_coding | tolerated_low_confidence(0.08) | benign(0.267) | TCGA-C8-A8HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |